Antigenic Peptides Or Proteins Patents (Class 530/806)
-
Patent number: 5173422Abstract: Monoclonal antibodies specific for the glycosylated lysine residue at position 525 in glycoalbumin and a method for producing such antibodies. The monoclonal antibodies are useful as reagents in immunoassays for the specific determination of glycoalbumin in human blood samples which is indicative of the severity of the diabetic condition. The monoclonal antibodies are secreted by hybridomas obtained by fusing a myeloma cell with a lymphocyte that has been taken from an animal, usually a mouse, immunized with a peptide immunogen and which produces antibody to the lysine 525 residue in glycoalbumin. The synthetic peptide immunogen comprises a peptide residue which includes an .epsilon.-amino glucosylated lysine and an adjacent amino acid sequence in which at least one of the amino acid units is in a position corresponding to the peptide sequence of human albumin adjacent to lysine 525, the glycosylated peptide residue being linked to an immunogenic carrier.Type: GrantFiled: May 3, 1990Date of Patent: December 22, 1992Assignee: Miles Inc.Inventors: William J. Knowles, Vincent T. Marchesi
-
Patent number: 5171666Abstract: The present invention relates to a novel tumor-associated antigen that is a cell-surface glycoprotein having a molecular weight in the range of 110,000-140,000 daltons that is present in a variety of carcinomas, including squamous cell carcinomas and adenocarcinomas. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of cancer.Type: GrantFiled: October 19, 1988Date of Patent: December 15, 1992Assignee: Eli Lilly and CompanyInventors: Magda C. Gutowski, David A. Johnson
-
Patent number: 5171839Abstract: The present invention relates to novel chemically synthesized nucleotides and novel chemically synthesized peptides which have been found to be effective in assaying for the presence of M. tuberculosis.Type: GrantFiled: August 23, 1990Date of Patent: December 15, 1992Inventor: Manuel E. Patarroyo
-
Patent number: 5171845Abstract: The invention concerns a new protein of approximately 17 KD, with angiogenic activity, a process for isolating it from mammalian milk, therapeutic compositions containing it, a process for detecting and/or determining the content of mammalian angiogenins, their homologues and their fragments. Said protein, of bovine origin, has a sequence of 125 aminoacids, 81 of which are common to human angiogenin, and a molecular weight of approximately 17 KD, and is extracted from mammalian milk. Application to the detection of mammalian angiogenin.Type: GrantFiled: August 21, 1989Date of Patent: December 15, 1992Inventors: Genevieve Spik, Andre Tarjar, Jean Montreuil
-
Patent number: 5156977Abstract: Monoclonal antibodies against atrial, natriuretic peptides are produced by deposited hybridoma cell lines 85031401 and 85031402 deposited with the European Collection of Animal Cell Cultures. The hybridoma are produced by fusion with cells from mammals which produce antibodies against atrial natriuretic peptides. The antibodies can thereafter be used in assays for the determination of the level of artrial natriuretic peptides in biological samples such as blood, plasma, serum, urine, lymph or cerebrospinal fluid.Type: GrantFiled: March 14, 1989Date of Patent: October 20, 1992Assignee: Bayer AktiengesellschaftInventors: Caludia Hirth, Frank-Joachim Morich, Dieter Neuser, Johannes-Peter Stasch
-
Patent number: 5143726Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.Type: GrantFiled: November 20, 1989Date of Patent: September 1, 1992Assignee: The Scripps Research InstituteInventors: George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
-
Patent number: 5126240Abstract: Hybridomas and their secreted paratopic molecules that immunoreact with apolipoprotein A-I are disclosed, as are assay methods for determining the presence and amount of apo A-I, and diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 9200, HB 9201, HB 9202, HB 9203 and HB 9204 are utilized.Type: GrantFiled: September 29, 1986Date of Patent: June 30, 1992Inventor: Linda K. Curtiss
-
Patent number: 5116725Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 8 to about 40 amino acid residues that includes the overlapping five and six amino acid residue sequences(i) --Gly--R.sup.1 --Gly--R.sup.2 --Gly--wherein R.sup.1 and R.sup.2 are amino acid residues selected from Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr with the provision that R.sup.1 and R.sup.2 are not both Gly; and(ii) --Gly--Ala--Gly--Gly--Ala--Gly--.The polypeptide contains at least 50 mole percent Gly residues. The diagnostic method and system are particularly useful for assaying for the stage of mononucleois disease, and the presence of nasopharynegeal carcinoma.Type: GrantFiled: November 4, 1987Date of Patent: May 26, 1992Assignee: Scripps Clinic and Research FoundationInventors: John H. Vaughan, Dennis A. Carson, Gary Rhodes, Richard Houghten, Richard S. Smith, John E. Geltosky
-
Patent number: 5110908Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization.Type: GrantFiled: November 9, 1989Date of Patent: May 5, 1992Assignee: Praxis Biologics, Inc.Inventors: Robert A. Deich, Gary Zlotnick, Bruce Green
-
Method of immunization with partially cationized substances and said partially cationized substances
Patent number: 5110794Abstract: A partially cationized protein-containing substance that exhibits enhanced immunogenicity as compared to the native protein-containing substance and is useful in mammalian immunization by oral or parenteral administration.Type: GrantFiled: March 16, 1990Date of Patent: May 5, 1992Assignee: Abbott LaboratoriesInventor: Jacob G. Michael -
Patent number: 5109113Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.Type: GrantFiled: August 6, 1987Date of Patent: April 28, 1992Assignees: Genentech, Inc., New York UniversityInventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.
-
Patent number: 5109115Abstract: The present invention discloses anti-bombesin monoclonal antibody and a method of detecting autocrine growth factor. A method and kit for screening and controlling growth of human SCLC has also been disclosed.Type: GrantFiled: December 5, 1988Date of Patent: April 28, 1992Assignee: The United States of America as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Frank F. Cuttitta, John D. Minna
-
Patent number: 5106760Abstract: Disclosed is a new mouse-mouse hybridoma tumor cell line A.T.C.C. No. HB8209. A monoclonal antibody produced by said cell line is specifically immunologically reactive with erythropoietin and with a polypeptide whose amino acid sequence is substantially duplicative of a sequence extent in erythropoietin. Disclosed also are procedures for isolation of erythropoietin by affinity purification and for quantitative detection of erythropoietin in fluid samples.Type: GrantFiled: June 30, 1988Date of Patent: April 21, 1992Assignee: Kirin-AmgenInventor: Joan C. Egrie
-
Patent number: 5102807Abstract: A protein which satisfies all the biological criteria which are characteristic of inhibin has been isolated from a gonadal source. The purification and characterization of inhibin and the use of the purified material to raise antibodies, the use of inhibin and said antisera in a quantative radioimmunoassay, and applications in vitro and in vivo of inhibin and antibody to inhibin, are described.There is provided a purified protein, inhibin, characterised in thata. the apparent molecular weight as determined by SDS-PAGE is 56,000.+-.1,000b. the isoelectric point is in the range 6.9-7.3c. the protein can bind specifically to Concanavalin A-Sepharosed the protein consists of two sub-units, characterized in thati. their apparent molecular weights as determined by SDS-PAGE are 44,000.+-.3,000 and 14,000.+-.2,000 respectively.ii. the isoelectric point of the 44,000 molecular weight sub-unit is in the range 6.0-7.0iii. the N-terminal amino acid sequences of the two sub-units are as described hereine.Type: GrantFiled: April 11, 1989Date of Patent: April 7, 1992Assignees: Biotechnology Australia Pty Ltd., Monash University, St. Vincent's Institute of Medical Research, Monash Medical CentreInventors: Henry G. Burger, David M. de Kretser, John K. Findlay, Francis J. Morgan, Milton T. W. Hearn, David Milne-Robertson, Robert G. Forage, Richard E. H. Weitenhall
-
Patent number: 5102663Abstract: The present invention provides a vaccine for stimulating or enhancing in a subject to whom the vaccine is administered, production of antibodies directed against 9-O-acetyl GD3 ganglioside comprising an amount of purified 9-O-acetyl GD3 ganglioside effective to stimulate or enhance antibody productionThis invention was made with government support under Grant Numbers CA-40532 and CA-43971, National Cancer Institute, Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in the invention.Type: GrantFiled: October 18, 1988Date of Patent: April 7, 1992Assignee: Sloan-Kettering Instutute for Cancer ResearchInventors: Philip O. Livingston, Gerd J. Ritter, Herbert F. Oettgen, Lloyd J. Old
-
Patent number: 5101014Abstract: The present invention comprises a method for the purification of the 69 kDa outer membrane protein of Bordetella B. pertussis and the protein purified therewith. A preferred embodiment comprises the purification of the 69 kDa protein from Bordetella B. pertussis strain Bp 353. The present process is advantageous in that it does not require or involve the use of biologics (such as monoclonal antibodies) and therefore simplifies the purification procedure and makes the resulting purified protein particularly advantageous for inclusion in acellular vaccines.Type: GrantFiled: February 10, 1989Date of Patent: March 31, 1992Assignee: United States of AmericaInventors: Drusilla L. Burns, Michael J. Brennan, Jeanine L. Gould-Kostka, Charles R. Manclark
-
Patent number: 5098997Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.Type: GrantFiled: September 1, 1988Date of Patent: March 24, 1992Assignee: Praxis Biologics, Inc.Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: 5095094Abstract: The proteins of the invention are specifically recognized by polyclonal anti-AC antibodies raised against purified AC preparations, devoid of adenylate cyclase CaM-activable activity and devoid of affinity for CaM.Type: GrantFiled: February 20, 1990Date of Patent: March 10, 1992Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche MedicaleInventors: Colette Brezin, Hoang-Oanh Nghiem, Jean Luc Boucaud, Jean M. Alonso
-
Patent number: 5093118Abstract: A cell wall protein of the fungus B. dermatitidis is isolated and purified. The protein is readily recognized by serum antibodies from animals having blastomycosis. The protein antigen can be labelled to provide an assay for detection of the disease, it can be used to stimulate specific lymphocyte response and thereby provide another assay for detection of the disease, it can be used to produce an immune response to B. dermatitidis, or it can be used to create antibodies to the protein.Type: GrantFiled: September 14, 1989Date of Patent: March 3, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Bruce S. Klein, Jeffrey M. Jones
-
Patent number: 5091303Abstract: A purified protein (p29) capable of binding autoantibodies present in the sera of individuals suffering from Wegener's granulomatosis. The invention also features a monoclonal antibody against the p29 protein and methods of diagnosing Wegener's granulomatosis.Type: GrantFiled: October 27, 1989Date of Patent: February 25, 1992Assignee: The General Hospital CorporationInventors: M. Amin Arnaout, Robert T. McCluskey, John L. Niles
-
Patent number: 5091177Abstract: The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. The method involves examining the human tissue for the presence of a glycolipid antigen having the characteristics of a ganglio-N-triosylceramide.Type: GrantFiled: May 11, 1990Date of Patent: February 25, 1992Assignee: OncogenInventors: Ingegerd Hellstrom, Joseph P. Brown, Karl E. Hellstrom, Diane Horn, Peter Linsley
-
Patent number: 5082776Abstract: The present invention provides a hybrid antigen polypeptide having both antigenicity of the ATLA encoded by gag gene and that of the ATLA encoded by env gene. The hybrid antigen can be produced in a large amount and it is applicable to serum diagnosis of patients infected with antigen polypeptides such as ATLV.Type: GrantFiled: January 31, 1990Date of Patent: January 21, 1992Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Susumu Sekine, Seiga Itoh
-
Patent number: 5081227Abstract: The invention relates to structural and regulatory DNA sequences encoding the germ cell ALP gene. These sequences differ at identified positions from the PLAP gene. Labelled nucleotide sequences complementary to germ cell ALP encoding nucleotide sequences but differing from PLAP may be used to detect the presence of the gene. The invention also relates to gene fragments specifying amino acid sequences which are specific to germ cell ALP and to antibodies raised against germ cell ALP-specific peptide fragments, their diagnostic and therapeutic uses.Type: GrantFiled: March 4, 1988Date of Patent: January 14, 1992Assignee: La Jolla Cancer Research FoundationInventor: Jose L. Millan
-
Patent number: 5071954Abstract: The invention relates to synthetic peptides which have amino acid sequences which correspond, in whole or in part, to the amino acid sequence of prothrombin and are antigenic, to the use thereof for the immunization of an animal and for the purification of specific antibodies, to antibodies against these peptides, and to the use of the antibodies for the determination of the fragments F.sub.2 /F.sub.1+2.Type: GrantFiled: August 17, 1988Date of Patent: December 10, 1991Assignee: Behringwerke AktiengesellschaftInventors: Hermann Pelzer, Werner Stuber
-
Patent number: 5066581Abstract: This invention provides a purified new differentiation antigen, designated NDA.sub.3, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 36,000 daltons.The invention also provides an antibody capable of specifically forming a complex with purified NDA.sub.3. Another aspect of the invention provides a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA.sub.3.The invention also pertains to a method for detecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.Type: GrantFiled: February 5, 1987Date of Patent: November 19, 1991Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Donald W. King
-
Patent number: 5057598Abstract: Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepaU.S. GOVERNMENT RIGHTSThe invention described herein may be manufactured, used and licensed by or for the U.S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.Type: GrantFiled: February 1, 1989Date of Patent: October 15, 1991Assignee: Centocor, Inc.Inventors: Matthew Pollack, Kenneth W. Hunter
-
Patent number: 5055396Abstract: The present invention describes a monoclonal antibody that is directed against an Apo AI/HLD epitope whose expression is substantially unaffected by deamidation. Also disclosed is a polypeptide capable of immunologically mimicking an Apo AI/HLD epitope whose expression is substantially unaffected by deamidation. Diagnostic systems and methods for determining the amount of Apo AI in a vascular fluid sample using a disclosed monoclonal antibody and/or a disclosed polypeptide are also described.Type: GrantFiled: November 2, 1987Date of Patent: October 8, 1991Assignee: Scripps Clinic and Research FoundationInventors: Linda K. Curtiss, Richard S. Smith
-
Patent number: 5053224Abstract: A method of inducing an immunological response to solid tumors is provided wherein anti-idiotype antibodies presenting an internal image of a tumor or antigen are administered to a patient. Monoclonal anti-idiotype antibodies and immortal B lymphocytes that produce them are also provided.Type: GrantFiled: August 26, 1987Date of Patent: October 1, 1991Inventors: Hilary Koprowski, Dorothee Herlyn, Elaine C. DeFreitas
-
Patent number: 5043340Abstract: Derivatives of 4-desacetyl VLB C-3 carboxhydrazide, active anti-tumor agents and useful as intermediates for active anti-tumor conjugates.Type: GrantFiled: April 3, 1990Date of Patent: August 27, 1991Assignee: Eli Lilly and CompanyInventor: George J. Cullinan
-
Patent number: 5032397Abstract: An immunogenic composition for a vaccine against human malaria. The composition contains one or more polypeptides that can be extracted from a schizont form of a human-malaria parasite such as a Plasmodium falciparum. The polypeptides have a molecular weight of 40,000 to 140,000, and they react with protective antibodies which come from a monkey resistant to the malaria parasite and which can, by in vivo transfer to a monkey sensitive to the parasite, protect the sensitive monkey against the parasite.Type: GrantFiled: July 10, 1989Date of Patent: July 16, 1991Assignee: Institut PasteurInventors: Philippe Dubois, Jean P. Dedet, Thierry G. Fandeur, Serge E. Pauillac, Christian P. Roussilhon, Luiz H. Pereira Da Silav, Jurg Gysin
-
Patent number: 5030621Abstract: A human anti-cancer vaccine is prepared by culturing human cancer cells, such as human melanoma cells, human lung cancer cells, human colon cancer cells, human breast cancer cells, and other human cancer cells in a serum-free medium. The cells are selected on the basis of expressing different patterns of cell surface tumor antigens and are adapted to and are grown in a serum-free medium. During culturing antigens of the cancer cells are shed into the culture medium. The culture medium, containing the shed cancer cell antigens, is then concentrated, such as by vacuum ultrafiltration. In some instances the vaccine is then treated with a non-ionic surfactant or detergent, such as Nonidet P-40 (NP-40), to break up aggregates and treated with a presevative, such as sodium azide, and then subjected to ultracentrifugation.Type: GrantFiled: February 22, 1990Date of Patent: July 9, 1991Inventor: Jean-Claude Bystryn
-
Patent number: 5028694Abstract: A purified antigenic protein has been obtained which is capable of inducing in a chicken an immune response conferring protection against infection by Eimeria necatrix or Eimeria tenella. The protein has a molecular weight of about 26,000 and is composed of two polypeptides joined by a disulfide bond. The two polypeptide subunits have molecular weights of about 18,000 and about 8,000, respectively. The gene encoding the protein has been sequenced and the amino acid sequence of the protein deduced therefrom.The protein and antigenic polypeptides having an amino acid sequence included within the protein may be incorporated into a vaccine for conferring upon a chicken active immunity against infection by E. necatrix or E. tenella.Type: GrantFiled: December 3, 1985Date of Patent: July 2, 1991Assignee: Solvay & Cie, S.A.Inventors: Karel Z. Mewman, Jr., John L. Tedesco, Thomas C. Gore, Gary R. Petersen, Virginia M. Brothers, James G. Files, Leland S. Paul
-
Patent number: 5021551Abstract: A method is disclosed for enhancement of the immunogenicity of a T cell immunogenic peptide which comprises adding an acidic amino acid at the N-terminus and/or a positive charge at the C-terminus of said peptide.Type: GrantFiled: January 18, 1989Date of Patent: June 4, 1991Assignee: Washington UniversityInventors: Paul M. Allen, Emil R. Unanue
-
Patent number: 5017558Abstract: Novel oligopeptides are provided having serologic activity for the a determinant of hepatitis B virus surface antigen. Included in the oligopeptide chain are a sequence of at least two cysteines and a lysine in proximity to the cysteines. The oligopeptides can find use in immunoassays, the formulation of vaccines, and the production of antisera.Type: GrantFiled: September 13, 1983Date of Patent: May 21, 1991Assignee: The Regents of the University of CaliforniaInventor: Girish N. Vyas
-
Patent number: 5015568Abstract: The sequence of the protein coding regions of the bcl-2 gene are provided as well as bacterial clones which produce the proteins. Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18. This translocation is involved in the majority of cases of human follicular lymphomas. One assay employs an antibody which is immunoreactive with a human protein which is over-expressed due to the chromosome translocation. Another assay involves measurement of the amount of mRNA which hybridizes to the gene proximal to the translocation break-point.Type: GrantFiled: July 9, 1986Date of Patent: May 14, 1991Assignee: The Wistar InstituteInventors: Yoshihide Tsujimoto, Carlo A. Croce
-
Patent number: 5006459Abstract: The present invention is directed to the measurement of soluble T cell growth factor receptors, soluble T cell differentiation antigens, or related soluble molecules or fragments thereof, and the use of such measurements in the diagnosis and therapy of diseases and disorders. The measurement of such molecules can be valuable in monitoring the effect of a therapeutic treatment on a subject, detecting and/or staging a disease in a subject, and in differential diagnosis of a physiological condition in a subject. These measurements can also aid in predicting therapeutic outcome and in evaluating and monitoring the immune status of patients.In specific embodiments, measurements of serum or plasma interleukin-2 receptor levels can be made, to detect or stage leukemia or lymphoma. In other embodiments, IL2R levels, or CD8 levels, can be used to differentially diagnose renal allograft rejection, as distinguished from Cyclosporin A nephrotoxicity.Type: GrantFiled: March 2, 1987Date of Patent: April 9, 1991Assignee: T Cell Sciences, Inc.Inventors: Patrick C. Kung, Stephen Ip, Michael Brown, Linda A. McKeen
-
Patent number: 5003046Abstract: The invention concerns a novel lymphocyte hybridoma and an antibody which may be generated from the hybridoma. The hybridoma and antibody have the internal designation LICR-LON-Fib 75. The origin, method of preparation and uses are discussed. The antibody has particular application in the diagnosis and treatment of cancer of the breast. A particular therapeutic treatment comprises harvesting a sample of bone marrow from a patient, subjecting the patient to treatment adapted to kill cancerous material including that within the bone marrow (possibly including the normal differentiated haemopoietic cells of the marrow), subjecting some or all of the sample to cytotoxic treatment with the antibody (or a toxin conjugate thereof) adapted to kill cancerous cell lines while leaving viable colony-forming units of bone marrow, and reintroducing the treated sample material to the blood stream of the patient.Type: GrantFiled: December 23, 1987Date of Patent: March 26, 1991Assignee: Ludwig Institute for Cancer ResearchInventors: Alexander M. Neville, Christopher S. Foster, Paul A. W. Edwards, Robert A. J. McIlhinney
-
Patent number: 4999421Abstract: The mRNA coded by the "anti-sense" strand of the complementary DNA produced by HTLV-I infection contains significant open reading frames. Cells infected by HTLV-I virus produce mRNA that is anti-sense to the viral RNA genome. Infected cells may produce proteins from the newly discovered mRNA. The production of the anti-sense in mRNA initiates from a newly discovered transcriptional promoter located within 1.8 kb from the 3' terminus of the viral genome. The mRNA, protein, and antibodies directed thereto can be used in the prevention, diagnosis, and treatment of HTLV-I infections.Type: GrantFiled: June 27, 1988Date of Patent: March 12, 1991Assignee: Triton Biosciences Inc.Inventors: Terence K. Brunck, David J. Larocca, John J. Monahan
-
Patent number: 4996194Abstract: Composition for the prevention and treatment of autoimmune diseases are provided which comprise as an active ingredient membrane material shed from autoimmune T lymphocytes, or activated T lymphocytes which are treated by a pressure application and releases process. There is also provided processes for obtaining such active materials and for preparing pharmaceutical compositions containing them.Type: GrantFiled: September 23, 1986Date of Patent: February 26, 1991Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Meir Shinitzky
-
Patent number: 4996297Abstract: The invention relates to antigenic preparations useful for inducing the production of antibodies in an individual which will bind to epitopes on zona pellucida. Also disclosed are immunogenic compositions and methods for immunizing an individual to enable the production of antibodies to zona pellucida antigens. Also disclosed are the use of these recombinant molecules and monoclonal antibodies thereto for immunocontraception or sterilization.Type: GrantFiled: October 7, 1987Date of Patent: February 26, 1991Assignee: Zonagen, Inc.Inventor: Bonita S. Dunbar
-
Patent number: 4994553Abstract: Several distinct peptide regions of the secreted form of purified human interleukin-1 species pI 6.8 have been found to exhibit characteristics associated with highly immunogenic protein moieties and are used to produce specific anti-peptide antibodies. The antibodies raised against the individual peptides are specific for the peptide used for their production and for IL-1, pI 6.8. The individual antibodies bind to both the precursor of IL-1, pI 6.8 and the mature or extracellular IL-1, pI 6.8.Type: GrantFiled: June 17, 1988Date of Patent: February 19, 1991Assignee: Merck & Co., Inc.Inventors: John A. Schmidt, Joshua S. Boger, Ellen B. K. Bayne
-
Patent number: 4985542Abstract: Purified glomerular proteoglycans are used as a basis for a diagnostic test for glomerulonephritis in humans involving an immunological reaction between the purified proteoglycans and patient area. A new method for purification of glomeruli proteoglycan antigens is described using guanidine extraction.Type: GrantFiled: May 17, 1989Date of Patent: January 15, 1991Assignee: The Rockefeller UniversityInventors: Howard Fillit, Shridhar P. Damle, John Zabriskie, John D. Gregory
-
Patent number: 4983387Abstract: Vaccines effective in the inhibition of infection caused by the family of retroviruses, HTLV-III, Human T-Cell Leukemia Virus, LAV, Lymphadenopathy-associated virus, ARV-2, AIDS-Related Virus, (AIDS and AIDS-Related Complex) have been developed from an antisera prepared against thymosin .alpha..sub.1 (T.alpha..sub.1), a thymic hormone, as well as from antisera to synthetic peptide fragments of T.alpha..sub.1 and antisera to synthetic peptide inclusive of amino acid positions 92-109 of the p17 gag core protein of HTLV-III, LAV and ARV-2. In this 18 amino acid primary sequence that is a 44 to 50% homology between the gag protein and T.alpha..sub.1. Immunoglobulin (IgG)- enriched preparations of the T.alpha..sub.1 antisera have enhanced activity in blocking viral replication. A diagnostic test capable of directly detecting the presence of HTLV-III, LAV, ARV-2 and related retroviruses associated with AIDS and ARC is also described.Type: GrantFiled: January 23, 1989Date of Patent: January 8, 1991Assignee: Viral Technologies Inc.Inventors: Allan Goldstein, Su-Sun Wang
-
Patent number: 4980456Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.Type: GrantFiled: April 6, 1987Date of Patent: December 25, 1990Assignees: Scripps Clinic and Research Foundation, Rorer Biotechnology Inc.Inventors: Dorothea H. Scandella, William N. Drohan, Theodore S. Zimmerman, Carol A. Fulcher
-
Patent number: 4971792Abstract: The present invention is directed to in vitro and in vivo immunodiagnosis and immunotherapy using monoclonal antibodies reactive with difucosyl blood group antigens Y-6 and B-7-2.Type: GrantFiled: March 27, 1987Date of Patent: November 20, 1990Assignee: The Wistar InstituteInventors: Zenon Steplewski, Hilary Koprowski, Magdelena Thurin
-
Patent number: 4965192Abstract: An interspecific antigen of Mycobacteria consists essentially of a mixture in substantially immunochemically pure form of a protein having a molecular weight of at least about 4.times.10.sup.6 Daltons and polysaccharide having a molecular weight of at least about 1.times.10.sup.6 Daltons, and has when subjected to cross-electrophoresis an immunoelectrophoretic precipitation pattern corresponding to A60-antigen of Mycobacteria bovis strain BCG. This antigen is effective for detecting the prior exposure of a subject to Mycobacterial infections by a cutaneous test.Type: GrantFiled: April 29, 1988Date of Patent: October 23, 1990Assignee: Anda BiologicalsInventor: Roland F. Maes
-
Patent number: 4957737Abstract: Synthetic peptides containing the epitopic sequence HTLV env (578-608) are useful as reagents in immunoassays for detection of AIDS antibodies, as immunogens for eliciting polyclonal or monoclonal antibodies against AIDS virus env protein and as components in an AIDS vaccine.Type: GrantFiled: August 21, 1989Date of Patent: September 18, 1990Assignee: Hoffmann-La Roche Inc.Inventors: Edgar P. Heimer, Premkumar E. Reddy
-
Patent number: 4957903Abstract: The invention relates to a fully solubilizable fibrin based composition, which is characterized by the combination that the fibrin is desAA-fibrin or desAA-fibrin from which the C-terminal portions of the .alpha.-chains have been removed by enzymatic digestion, and that the solubilizing agent is a tetrapeptide containing the amino acid sequence -L-prolyl-L-arginyl-, preferably glycyl-L-prolyl-L-arginyl-L-prolin.The full solubility of the fibrin makes possible new uses within the area of determination of important fibrinolytical parameters, and the invention also relates to three such important alternative uses. A first use according to the invention is the use of the composition in connection with detection or quantification of the activity of the enzyme tissue plasminogen activator.Type: GrantFiled: November 20, 1986Date of Patent: September 18, 1990Assignee: Biopool International, Inc.Inventor: Mats G. Ranby
-
Patent number: 4956452Abstract: Monoclonal antibodies effective in preventing infectious bursal disease in chickens, by neutralizing one or more virus strains thereof, have been isolated and obtained from deposited hybridomas. Vaccination of an entire poultry population with a vaccine prepared from these monoclonal antibodies gives a uniform level of protection against all strains of infectious bursal disease tested. The monoclonal antibodies were effective in inducing priming for an active anti-viral response in a heterologous host.Type: GrantFiled: June 12, 1987Date of Patent: September 11, 1990Assignee: The University of MarylandInventors: David B. Snyder, Warren W. Marquardt, Sammy L. Gorham, Dolores P. Lana
-
Patent number: RE34101Abstract: An antigen for the detection of Campylobacter pylori infections and an assay for the serological detection of Campylobacter pylori. The antigen includes high molecular weight cell-associated proteins purified from Campylobacter pylori. The antigen can be used in a variety of assays including radioimmunoassay, ELISA, latex agglutination, complement fixation, and indirect hemagglutination. Furthermore, the antigens can be combined with a solid support in kit form.Type: GrantFiled: March 19, 1991Date of Patent: October 13, 1992Assignee: Baylor College of MedicineInventors: Dolores G. Evans, Doyle J. Evans, David Y. Graham